Verve Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Verve Therapeutics
VERV Stock  USD 4.60  0.05  1.10%   
Verve Therapeutics financial statements provide useful quarterly and yearly information to potential Verve Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Verve Therapeutics financial statements helps investors assess Verve Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Verve Therapeutics' valuation are summarized below:
Gross Profit
-128.2 M
Market Capitalization
385.2 M
Enterprise Value Revenue
1.9662
Revenue
24.4 M
Earnings Share
(2.46)
There are over one hundred nineteen available fundamental trend indicators for Verve Therapeutics, which can be analyzed over time and compared to other ratios. All traders should should double-check Verve Therapeutics' current fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable. Market Cap is likely to climb to about 1.5 B in 2024. Enterprise Value is likely to climb to about 1.5 B in 2024

Verve Therapeutics Total Revenue

12.35 Million

Check Verve Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Verve Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 22.4 M, Interest Income of 8.3 M or Depreciation And Amortization of 3.3 M, as well as many indicators such as Price To Sales Ratio of 72.28, Dividend Yield of 0.0 or PTB Ratio of 1.57. Verve financial statements analysis is a perfect complement when working with Verve Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Verve Therapeutics Correlation against competitors.
For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.

Verve Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets421.5 M752.7 M168.8 M
Slightly volatile
Short and Long Term Debt Total70.2 M74.9 M47 M
Slightly volatile
Other Current Liabilities8.4 M10 M3.8 M
Slightly volatile
Total Current Liabilities23.1 M37 M10.7 M
Slightly volatile
Other Liabilities28 M26.7 M7.9 M
Slightly volatile
Property Plant And Equipment Net113.2 M107.8 M24.6 M
Slightly volatile
Accounts Payable4.1 M6.6 M3 M
Slightly volatile
Cash216.5 M206.2 M42.8 M
Slightly volatile
Non Current Assets Total120.5 M114.7 M26.6 M
Slightly volatile
Non Currrent Assets Other7.3 M6.9 M1.4 M
Slightly volatile
Other Assets3.9 M6.2 M1.7 M
Slightly volatile
Cash And Short Term Investments358.6 M624 M143.9 M
Slightly volatile
Common Stock Total Equity74.9 K71.3 K18.7 K
Slightly volatile
Common Stock Shares Outstanding57.9 M64.2 M50.3 M
Slightly volatile
Short Term Investments271.1 M417.8 M109.7 M
Slightly volatile
Liabilities And Stockholders Equity421.5 M752.7 M168.8 M
Slightly volatile
Non Current Liabilities Total85.1 M116.2 M54 M
Slightly volatile
Other Current Assets6.8 M8.1 M2.7 M
Slightly volatile
Total Liabilities108.2 M153.2 M64.7 M
Slightly volatile
Property Plant And Equipment Gross124.1 M118.2 M26.2 M
Slightly volatile
Total Current Assets365.5 M637.9 M146.5 M
Slightly volatile
Capital Stock43.6 K82 K17.3 K
Slightly volatile
Non Current Liabilities Other2.8 M2.9 M7.9 M
Slightly volatile
Net Working Capital342.4 M600.9 M135.9 M
Slightly volatile
Short Term Debt10.6 M20.4 M3.9 M
Slightly volatile
Common Stock43.6 K82 K17.3 K
Slightly volatile
Property Plant Equipment22.7 M21.6 M6.5 M
Slightly volatile
Net Receivables3.5 M5.9 M2.9 M
Pretty Stable
Capital Surpluse792.1 M1 B616.7 M
Slightly volatile
Inventory0.80.90.98
Slightly volatile
Deferred Long Term Liabilities16 M18 M19.6 M
Slightly volatile

Verve Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income22.4 M21.3 M3.6 M
Slightly volatile
Interest Income8.3 M7.9 M1.7 M
Slightly volatile
Depreciation And Amortization3.3 M5.5 M1.3 M
Slightly volatile
Selling General Administrative25.1 M49.9 M10.8 M
Slightly volatile
Other Operating Expenses119.6 M234.9 M52.4 M
Slightly volatile
Research Development94.5 M184.9 M41.6 M
Slightly volatile
Cost Of Revenue194.2 M184.9 M26.1 M
Slightly volatile
Total Operating Expenses119.6 M234.9 M52.4 M
Slightly volatile
Reconciled Depreciation5.1 M4.9 M1.1 M
Slightly volatile
Selling And Marketing Expenses4.4 M4.9 M5.3 M
Slightly volatile

Verve Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation36.9 M35.1 M7.1 M
Slightly volatile
Begin Period Cash Flow126.2 M120.2 M25.6 M
Slightly volatile
Other Cashflows From Financing Activities2 M2.1 M12.8 M
Slightly volatile
Depreciation5.7 M5.5 M1.2 M
Slightly volatile
Capital Expenditures7.1 M9.3 M3.7 M
Slightly volatile
Issuance Of Capital Stock68.7 M72.3 M74.6 M
Slightly volatile
Total Cash From Financing Activities226.4 M212.6 M94.5 M
Slightly volatile
End Period Cash Flow221.5 M211 M44.3 M
Slightly volatile
Change To Netincome27.1 M25.8 M12 M
Slightly volatile
Sale Purchase Of Stock37 M38.9 M309.6 M
Slightly volatile
Cash And Cash Equivalents Changes44.3 M45.6 M57.5 M
Slightly volatile
Other Cashflows From Investing Activities260.4 M387.2 M175 M
Slightly volatile
Change To Inventory809.6 K910.8 K991.8 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio72.2876.0845477
Slightly volatile
Days Sales Outstanding205183191
Pretty Stable
Stock Based Compensation To Revenue2.842.986610.4245
Slightly volatile
Capex To Depreciation1.621.701712.5765
Slightly volatile
EV To Sales61.6764.9199460
Slightly volatile
Days Of Inventory On Hand0.00.01.0E-4
Slightly volatile
Payables Turnover29.2627.87016.5136
Slightly volatile
Sales General And Administrative To Revenue4.034.24717.3105
Slightly volatile
Average Inventory0.40.450.49
Slightly volatile
Research And Ddevelopement To Revenue14.9415.729460.1327
Slightly volatile
Capex To Revenue0.750.78956.0108
Slightly volatile
Cash Per Share10.219.72262.8682
Slightly volatile
Days Payables Outstanding12.4413.09655.6 K
Slightly volatile
Income Quality0.540.74750.4893
Slightly volatile
Current Ratio10.4717.23918.2776
Slightly volatile
Receivables Turnover1.571.99391.8998
Slightly volatile
Graham Number26.8825.59828.183
Slightly volatile
Capex Per Share0.0960.14470.0688
Slightly volatile
Revenue Per Share0.190.18320.056
Slightly volatile
Interest Debt Per Share0.150.15880.6957
Pretty Stable
Debt To Assets0.01290.01351.1892
Slightly volatile
Operating Cycle205183191
Pretty Stable
Days Of Payables Outstanding12.4413.09655.6 K
Slightly volatile
Ebt Per Ebit1.260.89541.3171
Slightly volatile
Long Term Debt To Capitalization2.372.352.2311
Pretty Stable
Total Debt To Capitalization0.01590.01671.6479
Slightly volatile
Quick Ratio10.4717.23918.2776
Slightly volatile
Net Income Per E B T0.791.00140.9753
Slightly volatile
Cash Ratio5.855.57151.8176
Slightly volatile
Cash Conversion Cycle91.3717068.0933
Slightly volatile
Days Of Inventory Outstanding0.00.01.0E-4
Slightly volatile
Days Of Sales Outstanding205183191
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.221.06211.2026
Slightly volatile
Fixed Asset Turnover0.110.10910.0298
Slightly volatile
Debt Ratio0.01290.01351.1892
Slightly volatile
Price Sales Ratio72.2876.0845477
Slightly volatile
Asset Turnover0.01640.01560.0046
Slightly volatile

Verve Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.5 B894.6 M1.5 B
Slightly volatile
Enterprise Value1.5 B763.3 M1.5 B
Slightly volatile

Verve Fundamental Market Drivers

Cash And Short Term Investments624 M

Verve Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Verve Therapeutics Financial Statements

Verve Therapeutics investors use historical fundamental indicators, such as Verve Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Verve Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue48.6 M51 M
Total Revenue11.8 M12.3 M
Cost Of Revenue184.9 M194.2 M
Stock Based Compensation To Revenue 2.99  2.84 
Sales General And Administrative To Revenue 4.25  4.03 
Research And Ddevelopement To Revenue 15.73  14.94 
Capex To Revenue 0.79  0.75 
Revenue Per Share 0.18  0.19 
Ebit Per Revenue(18.98)(19.93)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Verve Stock Analysis

When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY